证券记录 · 已归档季度
INVA
Innoviva, Inc. · Healthcare · Biotechnology
19被追踪持有人
0Δ持有人
37.28M持有股份
$672.57M报告持仓市值
+0新建仓位
−1清仓
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 +1.3% · 净新建仓位 -5.3% · 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 613.20K | $13.00M | n/a | n/a |
| Q2 2026 | 106 | +3 | 60.79M | $1.34B | +7 | −3 |
| Q1 2026 | 105 | -1 | 60.91M | $1.40B | +5 | −7 |
| Q4 2025 | 107 | +1 | 64.49M | $1.28B | +2 | n/a |
| Q3 2025 | 19 | 0 | 37.28M | $672.57M | n/a | −1 |
| Q2 2025 | 17 | 0 | 33.81M | $670.62M | n/a | n/a |
| Q1 2025 | 14 | +1 | 14.22M | $254.33M | +1 | n/a |
| Q4 2024 | 13 | -1 | 11.88M | $203.26M | n/a | −1 |
| Q3 2024 | 13 | 0 | 9.24M | $175.70M | n/a | n/a |
| Q2 2024 | 13 | n/a | 8.36M | $134.81M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 9.46M | +3.5% | $172.30M | 0.0% | ▲ Add | 2 | SEC ↗ ×17 |
| 2 | The Vanguard Group ✦ (被动) | 7.39M | -0.6% | $130.41M | 0.0% | ▼ Trim | 2 | SEC ↗ ×8 |
| 3 | Renaissance Technologies ✦ | 4.63M | -3.6% | $83.83M | 0.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (被动) | 2.60M | +4.0% | $46.78M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Arrowstreet Capital ✦ | 2.36M | +38.0% | $43.05M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 6 | Marshall Wace ✦ | 1.65M | +23.9% | $30.14M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Millennium Management ✦ | 1.64M | -17.5% | $29.95M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 8 | Geode Capital Management ✦ (被动) | 1.68M | +3.2% | $29.04M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 9 | Morgan Stanley ✦ | 1.43M | n/a | $26.02M | 0.0% | n/c | 1 | SEC ↗ ×11 |
| 10 | Goldman Sachs Group ✦ | 1.20M | n/a | $21.98M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Citadel Advisors ✦ | 987.02K | -31.4% | $18.01M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 12 | D. E. Shaw & Co. ✦ | 735.73K | -28.0% | $13.43M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 13 | Two Sigma Investments ✦ | 522.24K | +57.4% | $9.53M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 14 | JPMorgan Chase ✦ | 437.97K | n/a | $7.99M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 15 | AQR Capital Management ✦ | 302.47K | +53.7% | $5.52M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 16 | Gotham Asset Management ✦ | 112.75K | +33.6% | $2.06M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 72.46K | +4.2% | $1.32M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 18 | Fidelity (FMR) ✦ | 37.31K | +7.5% | $680,937 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 19 | Wellington Management ✦ | 28.01K | +22.5% | $511,256 | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Norges Bank | $1.38M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 283 持有人, 74.79M 股份, $1.72B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
Jul 31
SC 13G: VANGUARD CAPITAL MANAGEMENT LLC
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据